Advertisement

Organisation › Details
UV-Cap Verwaltungs GmbH
UV Cap GmbH & Co KG (UV Cap) is a German Private Equity firm / Family Office focused on investing in healthcare companies at various stages of maturity. A particular area of investment focus is in precision medicine(s) and devices. An underlying commonality across deals is that UV Cap always takes an active and productive role in working with management. The family and team behind UV Cap are majority shareholders in Vetter Pharma, a +5.000 employee strong specialty Contract and Development Manufacturing Company (CDMO), manufacturing aseptic pharmaceutical products. Vetter Pharma counts the top 20 Pharma companies in the world among its customers. UV Cap is based in Ravensburg, Germany. *
![]() |
Start | 2017-02-03 existent |
Group | UV-Cap (Vetter family office) (Group) | |
Today | UV-Cap GmbH & Co. KG | |
![]() |
Industry | private equity |
Industry 2 | LIFE SCIENCES | |
![]() |
Person | Vetter, Udo J. (UV-Cap 201702 Founder + Managing Director) |
![]() |
Region | Ravensburg |
Country | Germany | |
Street | 57 Banneggstr. | |
City | 88214 Ravensburg | |
Tel | +49-751-14904 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Perfood GmbH. (11/30/20). "Press Release: German Digital Therapeutics Startup Perfood Closes 5m Euro Series A Led by Boehringer Ingelheim Venture Fund". Lübeck. | ||
Record changed: 2025-04-01 |
Advertisement

More documents for UV-Cap (Vetter family office) (Group)
- [1] Navigo Proteins GmbH. (4/1/25). "Press Release: Navigo Proteins Announces Strategic R&D Collaboration with SCK CEN to Develop Targeted Radiotheranostics". Halle (Saale) & Mol....
- [2] Navigo Proteins GmbH. (9/6/23). "Press Release: Navigo Proteins and Nostrum Biodiscovery Announce a Research Collaboration to Enhance Affilin Ligand Discovery Using Cutting-edge AI and Molecular Modeling Techniques". Halle (Saale) & Barcelona....
- [3] Navigo Proteins GmbH. (9/26/22). "Press Release: Navigo and Mannin Sign Agreement to Develop Innovative Affinity Ligand Against a Novel Drug for the Treatment of COVID-19". Halle (Saale)....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top